Aduhelm’s Goodbye: ENVISION Confirmatory Study To End In May, With BLA Withdrawal In November

Biogen faces complex logistics in shutting down a multinational trial with more than 200 sites and approximately 1,000 patients enrolled; company also is facing calls to publish data collected from the unfinished study as well as other aducanumab trials.